Literature DB >> 17085282

Mechanism of angioedema in first complement component inhibitor deficiency.

Alvin E Davis1.   

Abstract

Since shortly after the discovery that hereditary angioedema resulted from deficiency of first complement component (C1) inhibitor, the characterization of the mediator of angioedema has been a major goal. However, because C1 inhibitor regulates activation of both the contract and complement systems, identification of the mediator was not immediately accomplished. For a number of years, some studies appeared to indicate involvement of one system, whereas other studies suggested involvement of the other. However, the vast majority of the evidence accumulated over the past years indicates quite clearly that the major mediator is bradykinin. Therefore, unregulated contact system activation is the defect that leads directly to the development of angioedema.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085282     DOI: 10.1016/j.iac.2006.08.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  19 in total

1.  C1 esterase inhibitor (human).

Authors: 
Journal:  P T       Date:  2010-07

Review 2.  The new era of C1-esterase inhibitor deficiency therapy.

Authors:  Louanne Marie Tourangeau; Bruce L Zuraw
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

Review 3.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 4.  Hereditary angioedema in childhood: an approach to management.

Authors:  Didier G Ebo; Marjoke M Verweij; Kathleen J De Knop; Margo M Hagendorens; Chris H Bridts; Luc S De Clerck; Wim J Stevens
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 5.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

6.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Authors:  Marco Cicardi; Aleena Banerji; Francisco Bracho; Alejandro Malbrán; Bernd Rosenkranz; Marc Riedl; Konrad Bork; William Lumry; Werner Aberer; Henning Bier; Murat Bas; Jens Greve; Thomas K Hoffmann; Henriette Farkas; Avner Reshef; Bruce Ritchie; William Yang; Jürgen Grabbe; Shmuel Kivity; Wolfhart Kreuz; Robyn J Levy; Thomas Luger; Krystyna Obtulowicz; Peter Schmid-Grendelmeier; Christian Bull; Brigita Sitkauskiene; William B Smith; Elias Toubi; Sonja Werner; Suresh Anné; Janne Björkander; Laurence Bouillet; Enrico Cillari; David Hurewitz; Kraig W Jacobson; Constance H Katelaris; Marcus Maurer; Hans Merk; Jonathan A Bernstein; Conleth Feighery; Bernard Floccard; Gerald Gleich; Jacques Hébert; Martin Kaatz; Paul Keith; Charles H Kirkpatrick; David Langton; Ludovic Martin; Christiane Pichler; David Resnick; Duane Wombolt; Diego S Fernández Romero; Andrea Zanichelli; Francesco Arcoleo; Jochen Knolle; Irina Kravec; Liying Dong; Jens Zimmermann; Kimberly Rosen; Wing-Tze Fan
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

7.  C-reactive protein levels in hereditary angioedema.

Authors:  Z L M Hofman; A Relan; C E Hack
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

8.  Hereditary angioedema: New therapeutic options for a potentially deadly disorder.

Authors:  Frank J Eidelman
Journal:  BMC Blood Disord       Date:  2010-05-14

9.  Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema.

Authors:  Jonathan A Bernstein; Suzanne Coleman; Arturo J Bonnin
Journal:  J Cardiothorac Surg       Date:  2010-10-18       Impact factor: 1.637

10.  Depression and anxiety in patients with hereditary angioedema.

Authors:  Andrew S Fouche; Erika F H Saunders; Timothy Craig
Journal:  Ann Allergy Asthma Immunol       Date:  2013-06-25       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.